as 12-03-2024 4:00pm EST
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Founded: | 1983 | Country: | United States |
Employees: | N/A | City: | VIENNA |
Market Cap: | 40.1M | IPO Year: | 1987 |
Target Price: | N/A | AVG Volume (30 days): | 488.2K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.58 | EPS Growth: | N/A |
52 Week Low/High: | $0.54 - $3.23 | Next Earning Date: | 12-19-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3412.81% |
CVM Breaking Stock News: Dive into CVM Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Business Wire
a month ago
Business Wire
2 months ago
Business Wire
3 months ago
Business Wire
3 months ago
Business Wire
3 months ago
Zacks Small Cap Research
3 months ago
Business Wire
4 months ago
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.